Overview: Alkaptonuria Qualitative TestIntroduction: The Alkaptonuria Qualitative Test detects homogentisic acid in urine to diagnose alkaptonuria, a rare metabolic disorder causing dark urine, joint pain, or organ damage. Aligned with 2023 metabolic disorder guidelines, it uses spectrophotometry for high sensitivity, aiding in confirming this genetic condition. This test is critical for guiding supportive therapies, preventing complications, and improving outcomes in metabolic health.
Other Names: Alkaptonuria Test, Homogentisic Acid Assay.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards.
Historical Milestone: Alkaptonuria was identified in the 1900s. Spectrophotometric detection emerged in the 1970s, and by the 2000s, improved assays enhanced diagnostic specificity.
Purpose: Diagnoses alkaptonuria, guides therapy, and monitors disease in patients with dark urine or joint pain.
Test Parameters: 1. Homogentisic Acid
Pretest Condition: No fasting required. Collect urine at any time. Report dark urine, joint pain, or family history of metabolic disorders.
Specimen: 5-20 mL urine (sterile container). Transport in a biohazard bag within 2 hours, protected from light.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen, as homogentisic acid may degrade.
Medical History: Document dark urine, joint pain, or family history of alkaptonuria. Include current medications or symptoms of organ damage.
Consent: Written consent required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Uses spectrophotometry to detect homogentisic acid. Results are available in 1-2 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Light exposure or improper storage may degrade samples. Non-specific urine discoloration requires clinical correlation.
Clinical Significance: Positive results confirm alkaptonuria, prompting supportive therapy. Negative results may require genetic testing for confirmation.
Specialist Consultation: Consult a metabolic specialist or geneticist for result interpretation. Orthopedic referral is advised for joint issues.
Additional Supporting Tests: HGD gene testing or urine gas chromatography to confirm alkaptonuria.
Test Limitations: False negatives may occur in early disease. Non-specific urine changes require clinical correlation.
References: NORD Rare Disease Guidelines, 2023; Phornphutkul C, New England Journal of Medicine, 2022.
